Samsung Biologics is aiming to become ‘a full-service biopharmaceutical company’: creating a greater global footprint for its CDMO business, continuing to advance its biosimilars business, and laying the groundwork for novel drug development.
Speaking at the 29
th annual JP Morgan Healthcare Conference yesterday, John Rim – who took on the reins as CEO last month – unveiled the South Korean company s growth plans.
In 2021 it will speed up construction of its Plant 4 ‘super plant’, while it is also working to secure manufacturing facilities overseas.
Existing plants nearing capacity
Samsung Biologics work spans across development, manufacturing and laboratory testing services for biopharmaceutical products. In 2020 it signed $1.7bn in CMO contracts – a record-breaking figure – and opening the company’s first overseas CDO R&D center in San Francisco.